Immuno-oncology has emerged as a promising approach to treating lung cancer, which is one of the leading causes of cancer-related deaths worldwide. Immuno-oncology therapies work by stimulating the patient’s own immune system to recognize and attack cancer cells.
The current landscape of immuno-oncology in the lung cancer market is dominated by checkpoint inhibitors, such as pembrolizumab, nivolumab, and atezolizumab, which target specific proteins on cancer cells that suppress the immune system. These drugs have shown significant efficacy in treating non-small cell lung cancer (NSCLC) and have become standard of care for some patients.
However, there are still challenges that need to be addressed in the use of immuno-oncology therapies for lung cancer. For example, not all patients respond to these drugs, and there is a need to identify biomarkers that can predict response. There is also a need to develop combination therapies that can improve response rates and overcome resistance to current therapies.
The future outlook for immuno-oncology in the lung cancer market looks promising, with several new drugs and combination therapies in development. These include drugs that target different immune checkpoints, such as LAG-3 and TIGIT, and combination therapies that combine checkpoint inhibitors with other drugs, such as chemotherapy and targeted therapies.
In addition, there is growing interest in the use of personalized medicine approaches in immuno-oncology, where treatment is tailored to the patient’s individual cancer and immune system.
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Market Insight Lab journalist was involved in the writing and production of this article.